Exhaled nitric oxide in pregnant healthy and asthmatic women

L. Tamási, Anikó Bohács, András Bikov, Csilla Andorka, J. Rigó, G. Losonczy, I. Horváth

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background. Measurement of fractioned exhaled nitric oxide (FE NO) is useful for monitoring airway inflammation in asthma. Asthma is one of the most common diseases complicating pregnancy, and FENO may be helpful for monitoring asthma in pregnancy. However, some physiological alterations of FENO may be expected during healthy pregnancy due to vascular nitric oxide production. Until now no study assessed the level of FE NO in asthmatic pregnant patients. Objective. We aimed to assess the possible use and reproducibility of FENO measurements in pregnant asthmatic women. We compared FENO concentrations between four groups of subjects: healthy nonpregnant and pregnant females and asthmatic nonpregnant and pregnant patients. We also investigated the relationship between FE NO values and the level of asthma control in pregnant asthmatic patients. Methods. A total of 102 female subjects (35 healthy nonpregnant and 27 healthy pregnant females; 20 nonpregnant and 20 pregnant asthmatic women) were included in this cross-sectional study. Two FENO measurements were performed in each subject using an electrochemical sensor based device (NIOX MINO, Aerocrine, Solna, Sweden). Data are given as median with range. Results. The repeatability of FENO measurement was similar in pregnant and nonpregnant subjects. FENO levels did not differ significantly between healthy pregnant versus nonpregnant subjects (16.0 [8, 31] vs. 16.0 [9, 35] ppb). FENO levels were significantly increased in asthmatic women compared to healthy females (nonpregnant asthmatics: 38 [9, 54] ppb; p <0.001 vs. healthy nonpregnant; pregnant asthmatic patients: 28 [10, 56] ppb; p <0.05 vs. healthy pregnant). Conclusions. FENO level is not influenced by healthy pregnancy. In pregnant asthmatic patients FENO level is elevated compared to healthy pregnant subjects and correlates with the level of asthma control. Further studies are required to assess the use of FENO measurement to monitor asthma in this patient group.

Original languageEnglish
Pages (from-to)786-791
Number of pages6
JournalJournal of Asthma
Volume46
Issue number8
DOIs
Publication statusPublished - 2009

Fingerprint

Nitric Oxide
Asthma
Pregnancy
Healthy Volunteers
Pregnant Women
Sweden
Blood Vessels
Cross-Sectional Studies
Inflammation
Equipment and Supplies

Keywords

  • Asthma control
  • Asthmatics
  • FE
  • NIOX MINO
  • Nitric oxide
  • Pregnancy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Pediatrics, Perinatology, and Child Health

Cite this

Exhaled nitric oxide in pregnant healthy and asthmatic women. / Tamási, L.; Bohács, Anikó; Bikov, András; Andorka, Csilla; Rigó, J.; Losonczy, G.; Horváth, I.

In: Journal of Asthma, Vol. 46, No. 8, 2009, p. 786-791.

Research output: Contribution to journalArticle

Tamási, L. ; Bohács, Anikó ; Bikov, András ; Andorka, Csilla ; Rigó, J. ; Losonczy, G. ; Horváth, I. / Exhaled nitric oxide in pregnant healthy and asthmatic women. In: Journal of Asthma. 2009 ; Vol. 46, No. 8. pp. 786-791.
@article{7ede3aefa50c44d0a10db3db57007ce2,
title = "Exhaled nitric oxide in pregnant healthy and asthmatic women",
abstract = "Background. Measurement of fractioned exhaled nitric oxide (FE NO) is useful for monitoring airway inflammation in asthma. Asthma is one of the most common diseases complicating pregnancy, and FENO may be helpful for monitoring asthma in pregnancy. However, some physiological alterations of FENO may be expected during healthy pregnancy due to vascular nitric oxide production. Until now no study assessed the level of FE NO in asthmatic pregnant patients. Objective. We aimed to assess the possible use and reproducibility of FENO measurements in pregnant asthmatic women. We compared FENO concentrations between four groups of subjects: healthy nonpregnant and pregnant females and asthmatic nonpregnant and pregnant patients. We also investigated the relationship between FE NO values and the level of asthma control in pregnant asthmatic patients. Methods. A total of 102 female subjects (35 healthy nonpregnant and 27 healthy pregnant females; 20 nonpregnant and 20 pregnant asthmatic women) were included in this cross-sectional study. Two FENO measurements were performed in each subject using an electrochemical sensor based device (NIOX MINO, Aerocrine, Solna, Sweden). Data are given as median with range. Results. The repeatability of FENO measurement was similar in pregnant and nonpregnant subjects. FENO levels did not differ significantly between healthy pregnant versus nonpregnant subjects (16.0 [8, 31] vs. 16.0 [9, 35] ppb). FENO levels were significantly increased in asthmatic women compared to healthy females (nonpregnant asthmatics: 38 [9, 54] ppb; p <0.001 vs. healthy nonpregnant; pregnant asthmatic patients: 28 [10, 56] ppb; p <0.05 vs. healthy pregnant). Conclusions. FENO level is not influenced by healthy pregnancy. In pregnant asthmatic patients FENO level is elevated compared to healthy pregnant subjects and correlates with the level of asthma control. Further studies are required to assess the use of FENO measurement to monitor asthma in this patient group.",
keywords = "Asthma control, Asthmatics, FE, NIOX MINO, Nitric oxide, Pregnancy",
author = "L. Tam{\'a}si and Anik{\'o} Boh{\'a}cs and Andr{\'a}s Bikov and Csilla Andorka and J. Rig{\'o} and G. Losonczy and I. Horv{\'a}th",
year = "2009",
doi = "10.3109/02770900903090004",
language = "English",
volume = "46",
pages = "786--791",
journal = "Journal of Asthma",
issn = "0277-0903",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Exhaled nitric oxide in pregnant healthy and asthmatic women

AU - Tamási, L.

AU - Bohács, Anikó

AU - Bikov, András

AU - Andorka, Csilla

AU - Rigó, J.

AU - Losonczy, G.

AU - Horváth, I.

PY - 2009

Y1 - 2009

N2 - Background. Measurement of fractioned exhaled nitric oxide (FE NO) is useful for monitoring airway inflammation in asthma. Asthma is one of the most common diseases complicating pregnancy, and FENO may be helpful for monitoring asthma in pregnancy. However, some physiological alterations of FENO may be expected during healthy pregnancy due to vascular nitric oxide production. Until now no study assessed the level of FE NO in asthmatic pregnant patients. Objective. We aimed to assess the possible use and reproducibility of FENO measurements in pregnant asthmatic women. We compared FENO concentrations between four groups of subjects: healthy nonpregnant and pregnant females and asthmatic nonpregnant and pregnant patients. We also investigated the relationship between FE NO values and the level of asthma control in pregnant asthmatic patients. Methods. A total of 102 female subjects (35 healthy nonpregnant and 27 healthy pregnant females; 20 nonpregnant and 20 pregnant asthmatic women) were included in this cross-sectional study. Two FENO measurements were performed in each subject using an electrochemical sensor based device (NIOX MINO, Aerocrine, Solna, Sweden). Data are given as median with range. Results. The repeatability of FENO measurement was similar in pregnant and nonpregnant subjects. FENO levels did not differ significantly between healthy pregnant versus nonpregnant subjects (16.0 [8, 31] vs. 16.0 [9, 35] ppb). FENO levels were significantly increased in asthmatic women compared to healthy females (nonpregnant asthmatics: 38 [9, 54] ppb; p <0.001 vs. healthy nonpregnant; pregnant asthmatic patients: 28 [10, 56] ppb; p <0.05 vs. healthy pregnant). Conclusions. FENO level is not influenced by healthy pregnancy. In pregnant asthmatic patients FENO level is elevated compared to healthy pregnant subjects and correlates with the level of asthma control. Further studies are required to assess the use of FENO measurement to monitor asthma in this patient group.

AB - Background. Measurement of fractioned exhaled nitric oxide (FE NO) is useful for monitoring airway inflammation in asthma. Asthma is one of the most common diseases complicating pregnancy, and FENO may be helpful for monitoring asthma in pregnancy. However, some physiological alterations of FENO may be expected during healthy pregnancy due to vascular nitric oxide production. Until now no study assessed the level of FE NO in asthmatic pregnant patients. Objective. We aimed to assess the possible use and reproducibility of FENO measurements in pregnant asthmatic women. We compared FENO concentrations between four groups of subjects: healthy nonpregnant and pregnant females and asthmatic nonpregnant and pregnant patients. We also investigated the relationship between FE NO values and the level of asthma control in pregnant asthmatic patients. Methods. A total of 102 female subjects (35 healthy nonpregnant and 27 healthy pregnant females; 20 nonpregnant and 20 pregnant asthmatic women) were included in this cross-sectional study. Two FENO measurements were performed in each subject using an electrochemical sensor based device (NIOX MINO, Aerocrine, Solna, Sweden). Data are given as median with range. Results. The repeatability of FENO measurement was similar in pregnant and nonpregnant subjects. FENO levels did not differ significantly between healthy pregnant versus nonpregnant subjects (16.0 [8, 31] vs. 16.0 [9, 35] ppb). FENO levels were significantly increased in asthmatic women compared to healthy females (nonpregnant asthmatics: 38 [9, 54] ppb; p <0.001 vs. healthy nonpregnant; pregnant asthmatic patients: 28 [10, 56] ppb; p <0.05 vs. healthy pregnant). Conclusions. FENO level is not influenced by healthy pregnancy. In pregnant asthmatic patients FENO level is elevated compared to healthy pregnant subjects and correlates with the level of asthma control. Further studies are required to assess the use of FENO measurement to monitor asthma in this patient group.

KW - Asthma control

KW - Asthmatics

KW - FE

KW - NIOX MINO

KW - Nitric oxide

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=70350047276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350047276&partnerID=8YFLogxK

U2 - 10.3109/02770900903090004

DO - 10.3109/02770900903090004

M3 - Article

C2 - 19863281

AN - SCOPUS:70350047276

VL - 46

SP - 786

EP - 791

JO - Journal of Asthma

JF - Journal of Asthma

SN - 0277-0903

IS - 8

ER -